Prognostic Significance of the Cancer Stem Cell Markers CD133, CD44, and CD166 in Colorectal Cancer

Overview

Journal Cancer Invest

Specialty Oncology

Date 2009 Jul 24

PMID 19626493

Citations 103

Authors

David Horst

Lydia Kriegl

Jutta Engel

Thomas Kirchner

Andreas Jung

Affiliations

Soon will be listed here.

Abstract

CD133, CD44, and CD166 are cell surface markers that have recently been associated with colorectal cancer stem cells. As which of these markers has the greatest impact on patient prognosis is currently unknown, we compared their expression and prognostic significance in 110 colorectal adenocarcinomas. We demonstrate that expression of CD133 correlates with that of CD166, while both do not correlate with CD44. We show that CD133 is the best sole marker to predict low patient survival, while the combined analysis of all three markers may be superior in identification of low-, intermediate-, and high-risk cases of colorectal cancer.

Citing Articles

Informed by Cancer Stem Cells of Solid Tumors: Advances in Treatments Targeting Tumor-Promoting Factors and Pathways.

MacLean M, Walker O, Arun R, Fernando W, Marcato P Int J Mol Sci. 2024; 25(7).

PMID: 38612911 PMC: 11012648. DOI: 10.3390/ijms25074102.

Possible role of ALDH1 and CD44 in lip carcinogenesis.

Ortiz R, Gois G, Costa C, Costa N, Rodini C J Appl Oral Sci. 2023; 31:e20230227.

PMID: 38126564 PMC: 10786456. DOI: 10.1590/1678-7757-2023-0227.

Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy.

Borlongan M, Saha D, Wang H Stem Cell Rev Rep. 2023; 20(1):3-24.

PMID: 37861969 DOI: 10.1007/s12015-023-10639-6.

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.

Taib N, Merhi M, Inchakalody V, Mestiri S, Hydrose S, Makni-Maalej K J Transl Med. 2023; 21(1):235.

PMID: 37004094 PMC: 10067322. DOI: 10.1186/s12967-023-04073-y.

Chemotherapy induces feedback up-regulation of CD44v6 in colorectal cancer initiating cells through -catenin/MDR1 signaling to sustain chemoresistance.

Ghatak S, Hascall V, Karamanos N, Markwald R, Misra S Front Oncol. 2022; 12:906260.

PMID: 36330477 PMC: 9623568. DOI: 10.3389/fonc.2022.906260.